Infection · 2026
Long-term immune recovery under continuous antiretroviral therapy (ART) among ART-naive people living with HIV in two cohorts in Germany.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koppe Uwe, Pörtner Kirsten, Kollan Christian, Pantke Annemarie, Sailer Andrea, Dehmel Kerstin, Esser Stefan, Jensen Björn-Erik Ole, Rockstroh Jürgen Kurt, Schäfer Guido, Schürmann Dirk, Stoll Matthias, Wasmuth Jan-Christian, Kurth Tobias, Gunsenheimer-Bartmeyer Barbara, HIV-1 Seroconverter Cohort and the ClinSurv-HIV Cohort
Аннотация
OBJECTIVES: Immune recovery among people living with HIV (PWHIV) receiving antiretroviral therapy (ART) is determined analysing CD4 cell counts and the CD4/CD8 ratio. Recovery to ≥ 800 CD4 cells/µl and CD4/CD8 ratio ≥ 1 was associated with favourable outcomes. We investigated immune recovery over 10 years among ART-naive PWHIV on ART.
METHODS: Data were obtained from two German HIV cohorts, the HIV-1 Seroconverter study and the ClinSurv-HIV study, between 2003 and 2018. We included ART-naïve PWHIV starting with continuous ART and analysed CD4 cell counts and the CD4/CD8 ratio. The time to reaching immune thresholds was investigated using Kaplan-Meier analyses with inverse probability censoring weights.
RESULTS: Overall, 8,927 participants were included. At baseline, PWHIV had a median CD4 cell count of 257 (interquartile range [IQR] 124-393) cells/µl and CD4/CD8 ratio of 0.26 (IQR 0.14-0.43). After ten years, median CD4 counts increased to 630 (IQR 474-811) cells/µl and CD4/CD8 ratio to 0.84 (IQR 0.61-1.11). PWHIV with higher baseline CD4 values and without viral failure had higher median CD4 counts and CD4/CD8 ratios. The cumulative probability of achieving a CD4 count ≥ 800 cells/µl and/or CD4/CD8 ratio ≥ 1 over 10 years of ART were 54% for the CD4 threshold, 53% for the CD4/CD8 ratio threshold, and 32% for both thresholds. CD4 at baseline was identified as a predictor to achieve immune recovery in all models.
CONCLUSIONS: Early diagnosis and treatment, as well as effective antiviral therapy without viral failure, should be considered to achieve long-term immune recovery among PWHIV.
METHODS: Data were obtained from two German HIV cohorts, the HIV-1 Seroconverter study and the ClinSurv-HIV study, between 2003 and 2018. We included ART-naïve PWHIV starting with continuous ART and analysed CD4 cell counts and the CD4/CD8 ratio. The time to reaching immune thresholds was investigated using Kaplan-Meier analyses with inverse probability censoring weights.
RESULTS: Overall, 8,927 participants were included. At baseline, PWHIV had a median CD4 cell count of 257 (interquartile range [IQR] 124-393) cells/µl and CD4/CD8 ratio of 0.26 (IQR 0.14-0.43). After ten years, median CD4 counts increased to 630 (IQR 474-811) cells/µl and CD4/CD8 ratio to 0.84 (IQR 0.61-1.11). PWHIV with higher baseline CD4 values and without viral failure had higher median CD4 counts and CD4/CD8 ratios. The cumulative probability of achieving a CD4 count ≥ 800 cells/µl and/or CD4/CD8 ratio ≥ 1 over 10 years of ART were 54% for the CD4 threshold, 53% for the CD4/CD8 ratio threshold, and 32% for both thresholds. CD4 at baseline was identified as a predictor to achieve immune recovery in all models.
CONCLUSIONS: Early diagnosis and treatment, as well as effective antiviral therapy without viral failure, should be considered to achieve long-term immune recovery among PWHIV.